Hormonal
Subcutaneous semaglutide at 2.4 mg once weekly produces clinically significant weight loss (mean 14.9–17.4% reduction) in adults with obesity or overweight, with gastrointestinal side effects being the primary limiting factor.
For adults with obesity, weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle changes leads to substantial weight loss (approx. 15%). The main barrier is gastrointestinal side effects like nausea, which are usually mild and do not prevent weight loss. If injections are not preferred, oral semaglutide is an alternative, though subcutaneous administration may yield slightly greater weight loss.
Results showed that semaglutide combined with lifestyle modification leads to clinically significant weight loss in patients with obesity compared to placebo... In all STEP studies, subcutaneous administration of semaglutide at a dose of 2.4 mg once weekly consistently resulted in an average weight loss of 14.9–17.4% in participants without DM2...
Why this rating
Based on multiple Phase 3 randomized controlled trials (STEP 1-5) with large sample sizes.
Source
Semaglutide — effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP
O. R. Shabutdinova et al. · Problems of Endocrinology · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →